| 徐莹莹,韩正祥,徐宜全,马 浩,张 翔.华蟾素胶囊联合同步放化疗对局部晚期食管鳞癌患者血清疼痛介质和Th1、Th2相关细胞因子的影响[J].现代生物医学进展英文版,2023,(19):3788-3792. |
| 华蟾素胶囊联合同步放化疗对局部晚期食管鳞癌患者血清疼痛介质和Th1、Th2相关细胞因子的影响 |
| Effect of Huachansu Capsule Combined with Synchronous Radiotherapy and Chemotherapy on Serum Pain Mediators and Th1, Th2 Related Cytokines in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma |
| Received:April 04, 2023 Revised:April 27, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.19.038 |
| 中文关键词: 华蟾素胶囊 同步放化疗 局部晚期食管鳞癌 疼痛介质 辅助性T细胞1 辅助性T细胞2 细胞因子 |
| 英文关键词: Huachansu capsule Synchronous radiotherapy and chemotherapy Locally advanced esophageal squamous cell carcinoma Pain mediators Helper T cell 1 Helper T cell 2 Cytokines |
| 基金项目:江苏省卫健委高层次卫生人才"六个一工程"拔尖人才科研项目（LGY2020006） |
|
| Hits: 393 |
| Download times: 288 |
| 中文摘要: |
| 摘要 目的：探讨华蟾素胶囊联合同步放化疗对局部晚期食管鳞癌患者血清疼痛介质和辅助性T细胞（Th）1、Th2相关细胞因子的影响。方法：选取2018年2月~2020年2月期间来自徐州医科大学附属沭阳医院的80例局部晚期食管鳞癌患者。将患者按随机数字表法分组，分为对照组（n=40，同步放化疗）和研究组（n=40，华蟾素胶囊联合同步放化疗），对比两组疗效、疼痛情况[疼痛视觉模拟评分（VAS）、5-羟色胺（5-HT）、前列腺素E2 （PGE2）、P物质（SP）]、Th1、Th2相关细胞因子和不良反应发生率，采用Kaplan-Meier乘积限法绘制两组2年的生存曲线，采用Log-Rank检验比较两组生存资料的差异。结果：研究组的临床总有效率高于对照组（P<0.05）。研究组治疗后VAS评分、5-HT、PGE2、SP低于对照组（P<0.05）。研究组治疗后Th1相关细胞因子：白细胞介素（IL）-2、γ-干扰素（INF-γ）及肿瘤坏死因子-α（TNF-α）低于对照组（P<0.05），Th2相关细胞因子：IL-4、IL-10、IL-13高于对照组（P<0.05）。两组不良反应发生率组间对比无统计学差异（P>0.05）。研究组2年总生存（OS）率57.50%，明显高于对照组45.00%，研究组2年无进展生存（PFS）率42.50%，明显高于对照组35.00%（均P<0.05）。结论：华蟾素胶囊协同同步放化疗用于局部晚期食管鳞癌患者，临床总有效率进一步升高，同时还可减轻血清疼痛介质分泌，调节Th1、Th2相关细胞因子水平，提高患者生存率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Huachansu capsule combine with synchronous radiotherapy and chemotherapy on serum pain mediators and helper T cell (Th)1, Th2 related cytokines in patients with locally advanced esophageal squamous cell carcinoma. Methods: A total of 80 patients with locally advanced esophageal squamous cell carcinoma in Shuyang Hospital Affiliated to Xuzhou Medical University were selected from February 2018 to February 2020. According to the random number table,the patients were divided into control group(n=40, synchronous radiotherapy and chemotherapy) and study group(n=40, Huachansu capsule combined with synchronous radiotherapy and chemotherapy). The efficacy, pain status [visual analogue pain scale(VAS), 5-hydroxytryptamine(5-HT), prostaglandin E2 (PGE2), substance P (SP)], Th1, Th2 related cytokines and incidence of adverse reactions between the two groups were compared. The Kaplan-Meier product limit method was used to plot the 2-year survival curves of two groups, and the Log Rank test was used to compare the differences in survival data between the two groups. Results: The total clinical effective rate of the study group was higher than that of the control group (P<0.05). The VAS score, 5-HT, PGE2 and SP in the study group after treatment were lower than those in the control group(P<0.05). Th1 related cytokines: interleukin (IL)-2, interferon-γ (INF-γ) and tumor necrosis factor-α(TNF-α) in the study group after treatment were lower than those in the control group(P<0.05). Th2 related cytokines: IL-4, IL-10, and IL-13 were higher than those in the control group (P<0.05). There were no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). The 2-year overall survival(OS) rate of the study group was 57.50%, significantly higher than 45.00% of the control group. The 2-year progression free survival (PFS) rate of the study group was 42.50%, significantly higher than 35.00% of the control group (all P<0.05). Conclusion: Huachansu capsule combine with synchronous radiotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma patients, further increase in clinical total effective rate, at the same time, it can also reduce the secretion of serum pain mediators, regulate the levels of Th1 and Th2 related cytokines, improved patient survival rate. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
